Table 4.
Baseline information of validation cohort: anthropometry, maturity, plasma miR-145 level and serum bone turnover markers at first clinical visit (N = 51).
| Mean ± SD | Range | |
|---|---|---|
| Sample size | 51 | |
| Age (years) | 12.81 ± 0.97 | 10.53 – 14.39 |
| Initial maximum Cobb angle (o) | 23 ± 5 | 14 – 34 |
| Latest maximum Cobb angle(o) | 30 ± 11 | 14 – 59 |
| Anthropometry | ||
| Body weight (kg) | 41.2 ± 5.9 | 29.4 – 52.4 |
| Body height (cm) | 154.2 ± 7.1 | 130.0 – 167.6 |
| Arm span (cm) | 153.3 ± 8.2 | 127.5 – 169.2 |
| Maturity | ||
| Year since menarche (years) | 1.35 ± 0.86 | 0.07 – 3.10 |
| Menarche before first visitc | 33 (65%) | |
| Risser sign d | 0 (18) | 0 – 4 |
| 1 (4) | ||
| 2 (4) | ||
| 3 (7) | ||
| 4 (18) | ||
| Plasma micro-RNA level | −5.96 ± 1.41 | |
| ln (miR-145) a | −11.79 – −2.66 | |
| Serum bone turnover markers | 6.80 ± 0.50 | |
| ln (CTx) b | 6.13 ± 0.68 | 5.61 – 7.82 |
| ln (P1NP) b | 3.81 – 7.12 |
a
The value for “the plasma level of miR-145″ is the fold change relative to the level of the housekeeping reference miR-16. A log of the plasma level of miR-145 with the base e is calculated.
b
The level of CTX P1NP in the serum is represented as µg/L. A log of CTX/P1NP concentration with the base e is calculated and used.
c
Menarche status, 1 = onset of menarche is earlier than the first clinical visit and 0 = premenarche at first clinical visit.
d
Risser sign is presented as frequency of each level of Risser score.